News
12-12-2025, 05:48 PM
A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an improved method for predicting treatment benefits in patients with hormone receptor-positive (HR+) metastatic breast cancer that has spread primarily or exclusively to the bones.
More... (https://www.news-medical.net/news/20251212/Metabolic-imaging-enables-early-response-prediction-in-bone-dominant-metastatic-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20251212/Metabolic-imaging-enables-early-response-prediction-in-bone-dominant-metastatic-breast-cancer.aspx)